GLP-1 weight loss claims on TikTok: what the data says

What's this video probably claiming?

Accounts like @glp_1_weightloss_canada typically run a familiar playbook: personal transformation content, before-and-after framing, and enthusiastic claims about how fast GLP-1 medications like semaglutide or tirzepatide work. Given the Canadian angle, there's a decent chance this creator is discussing access, cost, or compounding pharmacy options, since brand-name Wegovy and Zepbound availability has been inconsistent in Canada. Expect claims along the lines of effortless appetite suppression, dramatic weight loss timelines, and possibly comparisons between different GLP-1 agents. Some creators in this space also wade into dosing territory, sharing what worked for them personally, which is where things get medically dicey fast. Without a transcript we're working from pattern recognition, but the pattern is pretty consistent across this content category.

What does the science actually show?

The clinical data on GLP-1 receptor agonists is genuinely impressive, and it doesn't need embellishment. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg weekly produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% mean weight loss over 68 weeks. These are real, peer-reviewed numbers from large randomized controlled trials. Liraglutide (Saxenda), the older daily-injection option, produced roughly 8% weight loss in the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM). Retatrutide, a triple agonist, is still in Phase 2 trials but showed up to 24% weight loss at 48 weeks (Jastreboff et al., 2023, NEJM). The science is solid. The gap is in how it gets translated on social media.

Where does the social media noise diverge from clinical reality?

Several distortions show up repeatedly in GLP-1 content. First, timeline compression. Trial results reflect 68 to 72 weeks of treatment, not the 8-week dramatic transformations TikTok often implies. Second, side effect minimization. Nausea, vomiting, and gastrointestinal distress affected 40 to 60% of trial participants, and discontinuation rates due to side effects ran around 7% in STEP 1. That rarely makes the show reel. Third, the compounding conversation is genuinely complicated in Canada. Health Canada does not authorize compounded semaglutide in the same way the FDA has addressed it in the U.S., and compounded products are not bioequivalent to regulated brand-name drugs. Creators who suggest otherwise are misrepresenting the regulatory situation. Fourth, individual variation is enormous. The trials report means, not guarantees. Some participants lost 5%, others lost 25%.

What should you actually know?

If you're watching GLP-1 content on TikTok and trying to separate signal from noise, a few things are worth anchoring to. These medications work through well-understood mechanisms: GLP-1 receptor agonism slows gastric emptying and reduces appetite signaling in the hypothalamus. Tirzepatide adds GIP receptor agonism, which appears to explain its edge over semaglutide in head-to-head data. Weight regain after stopping is real and documented: Davies et al. (2021, Diabetes, Obesity and Metabolism) showed participants regained two-thirds of lost weight within a year of stopping semaglutide. These are long-term medications for a chronic condition, not a one-time course. Anyone in Canada navigating access should be working with a licensed prescriber who understands the current regulatory environment, not making decisions based on a creator's personal protocol. FormBlends connects patients with regulated telehealth providers for exactly this reason.